ClinicalTrials.gg
CompletedNCT02013128Updated Oct 24, 2022

Ublituximab + Ibrutinib in Select B-cell Malignancies

A Phase 1/2 interventional study of Ublituximab and Ibrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma, sponsored by TG Therapeutics, Inc.. Completed at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-24.

Sponsored by TG Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
66
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell — none open to participants now, 1 under way, none of them phase 3. ublituximab · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
6th of 13
66 · median 51
Started
2014
the only one that year
Phase 1/2
2 of 13
none open now
Registered
5th of 13
by date
Lead sponsor
10 of 13
TG Therapeutics, Inc.

Among the 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 6th largest by enrollment, is the only one that started in 2014, is one of 2 in phase 1/2, and was the 5th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

None of the 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell is open now. The open studies under Leukemia, Lymphocytic, Chronic, B-Cell, anywhere →

About ublituximab

ublituximab: first FDA approval 2022 (BRIUMVI), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell as a file.
02

Study summary

The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with Ibrutinib in patients with advanced hematologic malignancies.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Mantle Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed Mantle Cell lymphoma (MCL) open for enrollment. The Chronic Lymphocytic Leukemia (CLL) enrollment arm is now closed.
  • to or relapsed after at least 1 prior treatment regimen
  • (ECOG) score of 0 to 2

Exclusion criteria

Exclusion Criteria:

  • Any major surgery, chemotherapy or immunotherapy within the last 21 days
  • Known virus, virus or infection
  • Autologous hematologic stem cell transplant within 3 months of study entry. Prior Allogeneic hematologic stem cell transplant is excluded.
  • Richter's transformation, prolymphocytic leukemia or primary central nervous system lymphoma
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Ublituximab + ibrutinib

    Ublituximab: IV infusion dose Days 1, 8 and 15 followed by maintenance infusions Ibrutinib: Fixed oral daily dose

    Drug: Ublituximab · Drug: Ibrutinib

Interventions

  • Ublituximab (IV infusion)

  • Ibrutinib oral daily dose

    Also known as: Ibrutinib (IMBRUVICA)

06

What researchers measure

Primary outcomes

  1. To evaluate the safety of ublituximab in combination with ibrutinib in patients with select B-cell malignancies

    To determine the incidence of adverse events, any potential abnormal laboratory results and any dose-limiting toxicities

    Time frame: 28 days (1 cycle of therapy)

Secondary outcomes

  1. Overall Response Rate

    To assess the overall response rate (ORR) in patients with hematologic malignancies treated with Ublituximab in combination with Ibrutinib

    Time frame: Up to 1 year

07

Study locations

18 sites
  • TG Therapeutics Investigational Trial Site
    Huntsville, Alabama 35805, United States
  • TG Therapeutics Investigational Trial Site
    Tucson, Arizona 85710, United States
  • TG Therapeutics Investigational Trial Site
    Santa Barbara, California 93105, United States
  • TG Therapeutics Investigational Trial Site
    Boulder, Colorado 80303, United States
  • TG Therapeutics Investigational Trial Site
    Niles, Illinois 60714, United States
  • TG Therapeutics Investigational Trial Site
    Urbana, Illinois 61801, United States
  • TG Therapeutics Investigational Trial Site
    Bethesda, Maryland 20817, United States
  • TG Therapeutics Investigational Trial Site
    Morristown, New Jersey 07962, United States
  • TG Therapeutics Investigational Trial Site
    Portland, Oregon 97213, United States
  • TG Therapeutics Investigational Trial Site
    Springfield, Oregon 97477, United States
  • TG Therapeutics Investigational Trial Site
    Greenville, South Carolina 29615, United States
  • TG Therapeutics Investigational Trial Site
    Memphis, Tennessee 38120, United States
  • TG Therapeutics Investigational Trial Site
    Austin, Texas 78705, United States
  • TG Therapeutics Investigational Trial Site
    Dallas, Texas 75230, United States
  • TG Therapeutics Investigational Trial Site
    Tyler, Texas 75702, United States
  • TG Therapeutics Investigational Trial Site
    Blacksburg, Virginia 24060, United States
  • TG Therapeutics Investigational Trial Site
    Fairfax, Virginia 22031, United States
  • TG Therapeutics Investigational Trial Site
    Vancouver, Washington 98684, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2014 to primary completion in Dec 2015, 23 months.

Of 50 industry-sponsored phase 1/2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 104. This study's 23 months is below that.

Counting every sponsor, half of 90 studies reached it within 78 months; a quarter within 51 and three quarters within 103.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2013
First posted
Dec 17, 2013
StartActual
Jan 6, 2014
Primary completionActual
Dec 2015
CompletionActual
Dec 2015
Results delay requested
Oct 21, 2022
Last update
Oct 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02013128
Responsible party
Sponsor
First posted
Dec 17, 2013
Start date
Jan 6, 2014
Primary completion
Dec 2015
Completion
Dec 2015
Last update
Oct 24, 2022

Study contacts

Jeff Sharman, MD
study chair · Willamette Valley Cancer Institute

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ublituximab

Start the discussion